DBV Technologies
↗Châtillon, France
DBV Technologies is a clinical-stage biopharmaceutical company pioneering the development of epicutaneous immunotherapy (EPIT™), a proprietary method of delivering biologically active compounds to the immune system through intact skin. The company's lead technology, the Viaskin™ patch, is designed to desensitize patients to allergens by targeting antigen-presenting cells in the epidermis while avoiding systemic distribution into the bloodstream.
The company is primarily focused on food allergies, with its lead candidate, Viaskin Peanut, currently in Phase 3 development for children and toddlers. After receiving a Complete Response Letter from the FDA in 2020 due to patch adhesion concerns, the company successfully redesigned the patch and reported positive Phase 3 VITESSE trial results in late 2025, positioning it for a potential market entry in 2026-2027.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$1M-$10M
Founded:2002
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$650M+
Investors:Baker Bros. Advisors, BPI France, Perceptive Advisors, RTW Investments
STOCK
Exchange:NASDAQ
Ticker:DBVT
Market Cap:$1.2B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (BLA Submission Planned H1 2026)
Modalities:Epicutaneous Immunotherapy (EPIT), Patch-based delivery
Active Trials:5
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:DBV Technologies Inc. (USA)
Key Partnerships:Nestlé Health Science (Previous diagnostic collaboration), Centre d'Immunologie de Marseille-Luminy (CIML)
COMPETITION
Position:Emerging Leader
Competitors:Aimmune Therapeutics (Nestlé), Alladapt Immunotherapeutics, Cour Pharmaceuticals, IgGenix
LEADERSHIP
Key Executives:
Daniel Tassé - CEO
Pharis Mohideen - Chief Medical Officer
Virginie Boucinha - CFO
Scientific Founders:Dr. Pierre-Henri Benhamou, Bertrand Dupont, Prof. Christophe Dupont
Board Members:Michel de Rosen (Chairman), Michael Goller, Timothy Morris, Adora Ndu
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with DBV Technologies. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.